Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

June 30, 2017

Study Completion Date

September 30, 2023

Conditions
Unilateral Retinoblastoma
Interventions
DRUG

Melphalan

Given IA

Trial Locations (12)

19104

Children's Hospital of Philadelphia, Philadelphia

27710

Duke University Medical Center, Durham

30322

Children's Healthcare of Atlanta - Egleston, Atlanta

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

M D Anderson Cancer Center, Houston

90027

Children's Hospital Los Angeles, Los Angeles

94143

UCSF Medical Center-Parnassus, San Francisco

94158

UCSF Medical Center-Mission Bay, San Francisco

06520

Yale University, New Haven

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT02097134 - Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma | Biotech Hunter | Biotech Hunter